Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
11/2007
11/08/2007US20070259903 Anti-viral uses for analogs of barbituric acid
11/08/2007US20070259902 Farnesyl transferase inhibiting 1,2-annelated quinoline enantiomer
11/08/2007US20070259901 Pharmaceutical compositions and use thereof
11/08/2007US20070259900 Polymorphs
11/08/2007US20070259899 2-(4-Morpholin-4-yl-phenylamino)-6-(2-trifluoromethyl-phenyl)-pyrido[2,3-d]pyrimidine-7-carboxylic acid (pyrrolidin-2-ylmethyl)-amide, for example; anticarcinogenic agents; improved activity, tolerability, selectivity or stability
11/08/2007US20070259898 NOVEL 2-AMINO-3,4-DIHYDRO-PYRIDO[3,4-D]PYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF beta-SECRETASE (BACE)
11/08/2007US20070259896 N-[3-(3-{[5-(4-Fluorophenyl)thieno[2,3-d]pyrimidin-4-yl]oxy}propoxy)phenyl]cyclopropanecarboxamide; PDE10 inhibitor; psychological, nervous system disorders; schizophrenia; cognition activators; drug abuse; antiepileptic agents; lupus; antitumor, -carcinogenic agents; hyperglycemica agents; sarcoidosis
11/08/2007US20070259895 MGluR5 modulators VI
11/08/2007US20070259894 Use of Atazanavir for Improving the Pharmacokinetics of Drugs Metabolized by Ugt1a1
11/08/2007US20070259893 Pyrazolopyrimidines
11/08/2007US20070259892 e.g. 1,3-benzothiazol-2-yl (2-chloral -4-pyrimidinyl)acetonitrile; Jun N -terminal kinase inhibitor; anticarcinogenic agent; neuronal disorders, autoimmune diseases, cardiovascular disordres
11/08/2007US20070259891 Heterocycle-Substituted Cyclic Urea Derivatives, Preparation Thereof And Pharmaceutical Use Thereof As Kinase Inhibitors
11/08/2007US20070259890 Compounds and Compositions as Ppar Modulators
11/08/2007US20070259889 Protein Binding Compounds
11/08/2007US20070259888 Novel Compounds
11/08/2007US20070259887 Inhibitors of polyq-aggregation
11/08/2007US20070259886 Dihydroxyphenyl isoindolylmethanones
11/08/2007US20070259885 Novel Crystal Form of(3-Cyano-1H-Indol-7-Yl)-[4-(4-Fluorophenethyl)Piperazin-1-Yl] Methanone, Hydrochloride
11/08/2007US20070259884 4,5-Dihydro-1H-pyrazole derivatives having potent CB1-antagonistic activity
11/08/2007US20070259883 Substitued A-Piperazingly Phenylpropionic Acid Derivatives As Hppar Alpha And/Or Hppar Gamma Agonists
11/08/2007US20070259882 3-substituted quinoline-4-carboxamide derivatives as nk-3 and nk-2 receptor antagonists
11/08/2007US20070259881 Substituted Imidazo Ring Systems and Methods
11/08/2007US20070259880 dipeptidyl peptidase IV (DPP-IV) inhibitors, useful for the prophylaxis or treatment of non-insulin dependent diabetes and obesity
11/08/2007US20070259879 Piperazine and piperidine biaryl derivatives
11/08/2007US20070259878 High throughput assay systems and methods for identifying agents that alter surface expression of integral membrane proteins
11/08/2007US20070259877 Piperazine Derivatives Useful for the Treatment of Gastrointestinal Disorders
11/08/2007US20070259876 3-(2,4-Diaminopteridin-6-yl)phenol or 6-(1H-Indol-4-yl)pteridine-2,4-diamine;phosphoinositide 3-kinase; enzyme inhibitors; vasculostatic agents; antiinflammatory agents; antiarthric agents; transplant rejecction; autoimmune diseases; anticarcinogenic agents
11/08/2007US20070259875 Triaryl substituted imidazole derivatives and taste-inhibiting uses thereof
11/08/2007US20070259874 Phosphodiesterase Inhibitors
11/08/2007US20070259873 Selective in presence of at least one other cathepsin isozyme; such as N-{-2-[2-(4-methoxy-phenylamino)-ethylcarbamoyl]-cyclohexyl}-3-methyl-benzamide
11/08/2007US20070259872 Inhibitors of soluble adenylate cyclase
11/08/2007US20070259871 Hydroxybenzamide Derivatives And Their Use As Inhibitors Of HSP90
11/08/2007US20070259870 Novel Pyridazinone Derivatives
11/08/2007US20070259869 inhibitors of Aurora protein kinases; antiproliferative agents; melanoma, myeloma, leukemia, lymphoma, neuroblastoma, and cancer; N-(4-(4-(3-methyl-1H-pyrazol-5-ylamino)-6-chloropyrimidin-2-ylthio)phenyl)cyclopentanecarboxamide
11/08/2007US20070259868 phosphodiesterase PDE4 inhibitor; preparing claimed 3-(dialkoxy)phenyl-4-aminopyran intermediate from the claimed 4-oxo compound starting with hydrobromination of the corresponding phenylacetylene; antiinflammatory for airways and skin; respiratory; bronchodilator
11/08/2007US20070259867 2-Phenyl or benzylphthalimide-5-carboxamide N-substituted with a piperidinyl-, pyrrolidinyl-, morpholinyl-, or piperazinylalkyl group (1-{2-[(1,3-dioxo-2-phenyl-2,3-dihydro-1H-isoindol-5-carbonyl)-amino]-ethyl}-piperidinium chloride); treating epilepsy, hypertension and stenocardia
11/08/2007US20070259866 Method of Adenovirus, HIV and HPV Prophylaxis
11/08/2007US20070259865 Agent for Promoting the Recovery from Dysfunction After the Onset of Central Neurological Disease
11/08/2007US20070259864 N-benzyl-N-{2-[7-(4-cyanobenzyl)-9-oxa-3,7-diazabicyclo[3.3.1]non-3-yl]ethyl}methane-sulfonamide; trial and ventricular arrhythmias; pharmacokinetics; electrophysiological activity; lowering daily clinical dose, lengthening duration of action; side effect reduction
11/08/2007US20070259862 3-{3-[(R)-1-(4-Methyl-5-pyrimidin-5-yl-4H-[1,2,4]triazol-3-yl)-pyrrolidin-2-yl]-isoxazol-5-yl}-benzonitrile; metabotropic glutamate receptors (mGluRs); have a limited ability of passing the blood-brain barrier
11/08/2007US20070259861 Combination therapy with non-selective COX inhibitors to prevent COX-related gastric injuries
11/08/2007US20070259860 MGluR5 modulators V
11/08/2007US20070259859 Muscarinic agonists to treat impulse control disorders
11/08/2007US20070259858 Novel bis-pyrrolo[2,1-c][1,4]benzodiazepine-anthraquinone conjugates and a process for the preparation thereof
11/08/2007US20070259857 Amorphous form of Olanzapine
11/08/2007US20070259856 Method for Activating Trpv4 Channel Receptors by Agonists
11/08/2007US20070259855 Thiazolyl-dihydro-indazole
11/08/2007US20070259854 Triazole Derivative or Salt Thereof
11/08/2007US20070259853 Tetrahydro-1h-1,2,6-triaza-azulene cannabinoid modulators
11/08/2007US20070259852 Such as 2-(2-hydroxycarbamoylmethyl-3-oxo-2,3-dihydro-benzo[1,4]thiazin-4-yl)-propionamide; peptidyl deformylase (PDF) inhibitors; for treatment of bacterial infections
11/08/2007US20070259851 4-(2-Oxo-1,4-dihydro-2H-quinazolin-3-yl)-piperidine-1-carboxylic acid (9-benzyl-8-oxo-3,6,7,8,9,10-hexahydro-2,3,9-triaza-(R)-cyclohepta[e]inden-7-yl)-amide; calcitonin gene-related peptide receptor antagonist; analgesic, antiinflammatory agent; migraine, neurogenic vasodilation, menopause, asthma
11/08/2007US20070259850 [9-(2,2-Dimethyl-propyl)-8-oxo-3,6,7,8,9,10-hexahydro-2,3,9-triaza-(S)-cyclohepta[e]inden-7-yl]-acetic acid methyl ester; calcitonin gene-related peptide receptor antagonist; analgesic, antiinflammatory agent; migraine, neurogenic vasodilation, circulatory shock, menopause, asthma
11/08/2007US20070259849 Azine-Carboxamides as Anti-Cancer Agents
11/08/2007US20070259848 N-({[1-(3,4-Dichloro-benzyl)-azetidin-3-ylmethyl]-carbamoyl}-methyl)-2-methoxy-benzamide; inflammatory or allergic condition such as an inflammatory or obstructive airways disease
11/08/2007US20070259847 1-(1,5-dimethyl-1H-pyrazole-3-carbonyl)piperidine-3-carboxylic acid [4-(5-cyclohexyl-2-methoxyphenyl)thiazol-2-yl]amide; chemokine receptor modulators
11/08/2007US20070259846 Dihydrothienopyrimidines; gastrointestinal disorders; cancer
11/08/2007US20070259845 Processes for the preparation of (3R,4S)-4-((4-benzyloxy)phenyl)-1-(4-fluorophenyl)-3-((S)-3-(4-fluorophenyl)-3-hydroxypropyl)-2-azetidinone, an intermediate for the synthesis of ezetimibe
11/08/2007US20070259844 Antiviral Compositions And Methods Of Using The Same
11/08/2007US20070259843 Methods and Compositions for Treatment of Macular and Retinal Disease
11/08/2007US20070259842 3 beta -1-(N',N'-dimethylaminopyridinium)-N-acetyloxy-19 beta ,28-epoxy-18 alpha -oleanan chloride; Plant fungicides and bactericides; antibiotic resistant staphylococcus and enterococcus; turf grasses; improved chemical resistance and stability
11/08/2007US20070259841 Combinations for the treatment of rheumatoid arthritis
11/08/2007US20070259840 Multi-Phase Contraceptive Preparation Based on a Natural Estrogen
11/08/2007US20070259839 3 beta -1-(N',N'-dimethylaminopyridinium)-N-acetyloxy-19 beta ,28-epoxy-18 alpha -oleanan chloride; Plant fungicides and bactericides; antibiotic resistant staphylococcus and enterococcus; turf grasses; improved chemical resistance and stability
11/08/2007US20070259838 17,20(Z)-Dehydro Vitamin D Analogs and Their Uses
11/08/2007US20070259837 Use of Non-Glucocorticoid Steroids for the Treatment of Muscular Dystrophy
11/08/2007US20070259836 e.g. (Z)-7-{(1R,2S,3R,5R)-3,5-Dichloro-2-[4-(1-hydroxy-hexyl)-phenyl]-cyclopentyl}-hept-5-enoic acid; prostaglandin EP2 selective agonists; glaucoma or ocular hypertension
11/08/2007US20070259835 Phosphinic Acid Derivatives
11/08/2007US20070259833 accelerating vascular endothelial repair with a low haemorrhage risk in the event of thrombotic injuries; promoting revascularization in ischemic tissues and vascular modelling in thrombotic injuries; produced by the marine bacterium Alteromonas
11/08/2007US20070259832 Nucleotide mimics and their prodrugs
11/08/2007US20070259829 Tolfenamic acid, diclofenac sodium, and diflunisal; non-steroidal anti-inflammatory drugs inhibited cancer cell growth, angiogenesis, metastasis of cancer cells by inducing degradation of Sp transcription factors; decreases expression of vascular endothelial growth factor; reducing toxicity of therapy
11/08/2007US20070259828 poly(N-(2-hydroxypropyl)methacrylamide) (PHPMA) and poly(N-[3-(dimethylamino)propyl]methacrylamide) (PDMAPMA); protecting siRNA, shRNA or miRNA from enzymatic degradation by complexing the siRNA, shRNA or miRNA with a hydrophilic/cationic block copolymer
11/08/2007US20070259827 Compositions and methods for enhancing discriminatory RNA interference
11/08/2007US20070259826 Chimeric (Double) Decoy
11/08/2007US20070259825 Transgenic Mammals and Cell Lines for the Identification of Glutamate Transporter Modulators
11/08/2007US20070259824 identifying a substance that down-regulates an immune response in an animal, comprising determining whether substance inhibits an interaction between factors in the CD26 signaling pathway, wherein substance inhibits the interaction between CD26 and caveolin-1
11/08/2007US20070259823 Diketo acids with nucleobase scaffolds: anti-HIV replication inhibitors targeted at HIV integrase
11/08/2007US20070259822 8a,11-bicyclic 8a-azalide derivatives
11/08/2007US20070259821 Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
11/08/2007US20070259813 Anti-Bacterial Composition Especially for Controlling Gram-Negative Bacteria, Comprising a Peptide and an Advantageously Hydrophobic Anti-Bacterial Agent
11/08/2007US20070259808 Comprising hydrolyzed gelatin, tryptophan and ingestible carrier; for decubitus ulcers/bariatric surgery; made up of the essential amino acids
11/08/2007US20070259787 Insecticide Compositions
11/08/2007US20070259383 Novel Genes involved in Epidermal differentiation, and uses thereof
11/08/2007US20070259057 Wrinkle Reduction Agent, Lipolysis Accelerator, Composition for External Use on Skin, and Food or Beverage Composition
11/08/2007US20070259056 Anti-Tumour Terpene Compounds
11/08/2007US20070259054 Improved via addition of sweetener, increase in potassium content, and/or by increase in citric acid content
11/08/2007US20070259053 Inhibition of nephrotoxicity induced by Trasylol® and like agents
11/08/2007US20070259051 Method of treating a condition associated with phosphorylation of TASK-1
11/08/2007US20070259050 Combined Cosmetic or Therapeutic Preparation
11/08/2007US20070259049 Process for preparing lansoprazole
11/08/2007US20070259048 Mixture of micronized formoterol fumarate dihydrate salt (< 0.6 w/w) and a micronised pharmaceutically acceptable carrier/diluent, lactose; high storage stability such that the decomposition of formoterol will be < 2.0% (w/w) when stored in a powder device at 40 degrees C. and 75% relative humidity
11/08/2007US20070259045 Alcohol Resistant Dosage Forms
11/08/2007US20070259044 Compositions comprising biomembrane sealing agent for treatment of neuronal injury, and methods of use
11/08/2007US20070259043 Halide-free glucosamine-therapeutic drug salt compositions
11/08/2007US20070259041 Solid dosage formulations
11/08/2007US20070259040 Novel triptan formulations and methods for making them
11/08/2007US20070259039 Method for the treatment of acne
11/08/2007US20070259037 Method and composition for treatment of inflammatory conditions
11/08/2007US20070259034 Highly absorbable coenzyme q10 composition and method of producing same
11/08/2007US20070259033 Controlled release formulations exhibiting an ascending rate of release
11/08/2007US20070259028 used as plaster on skin; comprises adherent layer, intermediate membrane, and drug reservoir layer sequentially from skin side, wherein drug reservoir layer comprises an antidementia drug, an aminated polymer, a polyhydric alcohol, and carboxylic acid esters
1 ... 3511 3512 3513 3514 3515 3516 3517 3518 3519 3520 3521 3522 3523 3524 3525 3526 3527 3528 3529 3530 3531 ... 7860